A Phase II Trial of Homoharringtonine and Caracemide in the Treatment of Patients with Advanced Large Bowel Cancer
| Autor: | Thomas J. Smith, Robert F. Asbury, Charles M. Strnad, Thomas L. Goodman, Daniel G. Haller, Stuart R. Lipsitz, Robert S. Witte, George Wilding |
|---|---|
| Rok vydání: | 1999 |
| Předmět: |
Adult
Male Harringtonines medicine.medical_specialty Colorectal cancer medicine.medical_treatment Antineoplastic Agents Cohort Studies Sepsis Caracemide Carcinoma Humans Hydroxyurea Medicine Pharmacology (medical) Aged Neoplasm Staging Pharmacology Chemotherapy Leukopenia business.industry Middle Aged medicine.disease Surgery Oncology Homoharringtonine Ambulatory Female medicine.symptom Colorectal Neoplasms business |
| Zdroj: | Investigational New Drugs. 17:173-177 |
| ISSN: | 1573-0646 0167-6997 |
| DOI: | 10.1023/a:1006327418043 |
| Popis: | Twenty-four previously untreated, ambulatory patients with advanced colorectal carcinoma were treated with either caracemide (11 patients) or homoharringtonine (13 patients). No objective responses were observed in any of the treatment cohorts. Caracemide was well tolerated with the exception of one death due to sepsis. On the homoharringtonine arm one patient died of pulmonary sepsis, one patient experienced grade 4 leukopenia requiring more than 4 weeks of recovery, and an additional patient developed grade 4 renal failure. These severe and unexpected complications caused early termination of accrual to the homoharringtonine arm of the study. These agents have no activity in the treatment of advanced colorectal carcinoma. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink